This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Ozanimod for treating moderately to severely active ulcerative colitis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Ozanimod for treating moderately to severely active ulcerative colitis

Ozanimod

  • is a sphingosine-1-phosphate receptor (S1PR) modulator originally approved to treat relapsing forms of multiple sclerosis
  • binds with high affinity to S1PR1 and S1PR5
  • mechanism of action by which ozanimod produces its therapeutic effects in ulcerative colitis is currently unknown, it may be associated with the ozanimod-induced reduction of lymphocyte migration into the intestine (1)

NICE state:

  • Ozanimod is recommended as an option for treating moderately to severely active ulcerative colitis in adults, only if:
    • conventional treatment cannot be tolerated or is not working well enough and infliximab is not suitable, or
    • biological treatment cannot be tolerated or is not working well enough, and
    • the company provides it according to the commercial arrangement
  • the NICE committee commented
    • "..Clinical trial evidence shows that ozanimod is more effective than placebo for treating moderately to severely active ulcerative colitis. There is no direct evidence comparing ozanimod with standard treatments that are offered after conventional treatment, but indirect comparisons suggest that it is likely to be as effective as some of them.."

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.